Adage Capital Partners
THRX

Adage Capital Partners’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Adage Capital Partners’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-761,589
Closed -$8.78M – 1158
2022
Q1 		$8.78M Hold
761,589
– – 0.02% 729
2021
Q4 		$9.66M Buy
+761,589
New +$11.5M 0.02% 709

Other funds holding THRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Adage Capital Partners's THRX Position: Q2 2022 in Review

Adage Capital Partners sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q2 2022, closing a stake of 761,589 shares — an estimated $8.78M sold.

Adage Capital Partners first reported a position in THRX in Q4 2021 and held it in 2 quarters. The position peaked at $9.66M in Q4 2021. 51 funds tracked by Wall St. Rank hold THRX as of Q2 2022.

  • Adage Capital Partners reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Adage Capital Partners sold 761,589 Theseus Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $8.78M.
  • Adage Capital Partners first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Adage Capital Partners's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $9.66M in Q4 2021.
  • 51 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.